Emergence of undifferentiated urothelial carcinoma after pembrolizumab treatment for patient with invasive urothelial bladder cancer: A case report

An 83-year-old man received pembrolizumab treatment after anticancer chemotherapy with gemcitabine and cisplatin for advanced bladder cancer. Pathological findings revealed invasive urothelial carcinoma with squamous differentiation before treatment. After seven courses of pembrolizumab treatment, t...

Full description

Saved in:
Bibliographic Details
Published inSAGE open medical case reports Vol. 8; p. 2050313
Main Authors Hasegawa, Moto, Hasegawa, Go, Ikeda, Yohei, Hara, Noboru, Nishiyama, Tsutomu
Format Journal Article
LanguageEnglish
Published London, England SAGE Publications 01.06.2020
Sage Publications Ltd
SAGE Publishing
Subjects
Bladder cancer
Case Report
Case reports
Immunotherapy
Monoclonal antibodies
Targeted cancer therapy
Invasive bladder cancer
pembrolizumab
differentiated urothelial cancer before treatment
programmed death-ligand 1 expressions in tumor tissue
undifferentiated urothelial cancer after pembrolizumab treatment
Online AccessGet full text

Cover

More Information
Summary:An 83-year-old man received pembrolizumab treatment after anticancer chemotherapy with gemcitabine and cisplatin for advanced bladder cancer. Pathological findings revealed invasive urothelial carcinoma with squamous differentiation before treatment. After seven courses of pembrolizumab treatment, the tumor disappeared. After 15 courses of the treatment, the tumor regrew. Pathological findings revealed invasive undifferentiated urothelial carcinoma consisting of relatively small tumor cells of the same size as lymphocytes, negative for neuroendocrine markers. Programmed death-ligand 1 expressions in tumor tissue changed from positive before treatment to negative after pembrolizumab treatment.
ISSN:2050-313X
2050-313X
DOI:10.1177/2050313X20932694